Dr. Dunleavy has served as Inovalon’s Chief Executive Officer since his organization of the company’s predecessor companies in 1998, as Chairman of the Board of Directors since the creation of the Board in 2006 through 2021, and as President of the Company from its foundation until May of 2014. Dr. Dunleavy is responsible for the overall execution of the company’s business plan, strategic relationships, and the identification and realization of the Company’s product strategy and vision.
During his tenure at Inovalon, Dr. Dunleavy has worked extensively with a wide array and number of healthcare organizations, regulatory and oversight bodies, and technology companies examining the growing role of data within healthcare, and its ability to drive meaningful insight and improvement for its constituents. Driven by a desire to help empower a data-driven transformation of healthcare, Dr. Dunleavy has led Inovalon from its origins to its current industry-leading position leveraging advanced, cloud-based platforms that are informed by data pertaining to more than one million physicians, 594,000 clinical facilities, 348 million unique patients, and 68 billion medical events empowering meaningful improvements in clinical outcomes and economics across the entire healthcare ecosystem.
Dr. Dunleavy received a bachelor’s degree in biology modified with engineering with high honors from Dartmouth College where his studies and work focused upon the neurosciences, computer sciences, and electrical engineering with his honors thesis focused on the computer simulation of artificial human cerebellar functional units. Dr. Dunleavy earned his doctorate in medicine from Harvard Medical School, completed his medical residency at The Johns Hopkins Hospital in Baltimore, Maryland, practiced, and was Board Certified in Internal Medicine. He has authored or co-authored a number of scientific journal articles, abstracts, and proprietary research papers, has presented his work and materials at multiple national and international conferences, and has been awarded multiple U.S. patents pertaining to the real-time aggregation, analysis, and application of healthcare data.
What is Keith R. Dunleavy's net worth?
The estimated net worth of Keith R. Dunleavy is at least $18.20 million as of October 30th, 2020. Dr. Dunleavy owns 660,000 shares of Inovalon stock worth more than $18,199,500 as of April 23rd. This net worth approximation does not reflect any other assets that Dr. Dunleavy may own. Learn More about Keith R. Dunleavy's net worth.
How do I contact Keith R. Dunleavy?
Has Keith R. Dunleavy been buying or selling shares of Inovalon?
Keith R. Dunleavy has not been actively trading shares of Inovalon in the last ninety days. Most recently, on Friday, October 30th, Keith R. Dunleavy bought 60,000 shares of Inovalon stock. The stock was acquired at an average cost of $19.62 per share, with a total value of $1,177,200.00. Following the completion of the transaction, the chief executive officer now directly owns 660,000 shares of the company's stock, valued at $12,949,200. Learn More on Keith R. Dunleavy's trading history.
Who are Inovalon's active insiders?
